Document is current
Any future updates will be listed below
-
Authors
Rondeau, Justin D. https://orcid.org/0009-0003-1239-4633
Lipari, Sara https://orcid.org/0009-0008-4058-7922
Mathieu, Barbara https://orcid.org/0000-0003-3398-5144
Beckers, Claire https://orcid.org/0000-0003-4678-6865
Van de Velde, Justine A. https://orcid.org/0000-0003-0054-9020
Mignion, Lionel https://orcid.org/0000-0002-9426-8600
Da Silva Morais, Mauricio https://orcid.org/0000-0001-7718-1629
Kreuzer, Marvin
Colauzzi, Ilaria https://orcid.org/0009-0008-0191-1769
Capeloa, Tania
Pruschy, Martin https://orcid.org/0000-0002-3124-9015
Gallez, Bernard https://orcid.org/0000-0002-5708-1302
Sonveaux, Pierre
- License Information
-
More Information
Article History
Received: 2 September 2024
Revised: 10 December 2024
Accepted: 17 December 2024
First Online: 27 December 2024
Competing interests
: P Sonveaux and T Capeloa are inventors of patent application WO2022/243541 A1 “Molecular signature for assessing the responsiveness of cancer to mitochondria-targeted antioxidants”. P Sonveaux and JD Rondeau are inventors of patent application EP24186067.5 “Mitochondrially-targeted antioxidant compound for use in radiation therapy”. P Sonveaux is involved in a clinical collaboration with Antipodean Pharmaceuticals Inc. for the prevention of BC metastasis. Authors declare no other conflict of interest. Antipodean Pharmaceuticals Inc. and MitoQ Inc., who own the rights on the MitoQ molecule, were not involved in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.
